Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


5645 - Long-term efficacy of denosumab in giant cell tumor of bone: results of an open-label phase 2 study


09 Sep 2017






Emanuela Palmerini


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


E. Palmerini1, J. Blay2, A. Le Cesne3, P. Reichardt4, P. Rutkowski5, H. Gelderblom6, R.J. Grimer7, A. Feng8, D. Jandial9, S. Chawla10

Author affiliations

  • 1 -, Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 2 Medicine, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, 13125 - Berlin/DE
  • 5 Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, 02781 - Warsaw/PL
  • 6 Medical Oncology, Leiden University Medical Center (LUMC), Leiden/NL
  • 7 Medical Oncology, Royal Orthopaedic Hospital, NHS Foundation, Birmingham/GB
  • 8 Biostatistics, Amgen Inc., Thousand Oaks/US
  • 9 Oncology, Amgen Inc., Thousand Oaks/US
  • 10 Oncology, Sarcoma Oncology Center, 90403 - Santa Monica/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5645


Giant cell tumor of bone (GCTB) is a progressive osteolytic tumor with proven response to denosumab when unresectable or at high surgical risk. We report on the primary analysis of this phase 2 study.


Patients (pts) were enrolled with unresectable GCTB (Cohort 1), resectable GCTB with planned high morbidity surgery (Cohort 2), and prior GCTB study pts (Cohort 3). Denosumab was given 120 mg SC every 4 weeks with loading doses on days 8 and 15. The primary endpoint was safety; efficacy endpoints included proportion of Cohort 2 pts without surgery, and progression-free survival for all pts.


Baseline characteristics and key safety results for 532 pts are shown in the Table. Median follow-up was 55 months (IQR 34, 75) in Cohort 1 and 44 months (IQR 26, 59) in Cohort 2. Overall response rates were 99% in Cohorts 1 and 2. Of 267 Cohort 1 pts, 19 (7%) ended denosumab for GCTB progression. Kaplan Meier (KM) estimates (95% CI) for GCTB progression in these pts were 4% (2–7%) at week 49, and 7% (4–10%) at week 98. 135 Cohort 1 pts ended denosumab without GCTB progression, and 34 (25%) recurred with a KM median estimate (95% CI) of 39 (18, NE) months. Of 248 Cohort 2 pts with planned surgery, 63% underwent surgery and 37% continued with denosumab only. Following surgery, 27% pts had a recurrence, higher after curettage than resection (34 vs 12%).



N = 532 n (%)
Women301 (57)
Adolescentsa28 (5)
Median age (range)33 (13–83)
Adverse Events (AE)n = 526 AllRelatedb
Osteonecrosis of jawc28 (5.3)28 (5.3)
Serious AEs138 (26.2)42 (8.0)
Fatal AEs10 (1.9)2 (0.4)
AEs leading to study discontinuation46 (8.7)27 (5.1)

Skeletally mature adolescents defined as age 12-17 years with radiographic evidence of at least 1 mature long bone with closed growth epiphyseal plate.

Patients who received ≥1 dose of denosumab (safety analysis set)


Considered by investigator to be possibly related to denosumab


Positively adjudicated by two independent reviewers

Fatal AEs: Respiratory failure (2), Post radiation osteosarcoma* (1), Giant cell rich osteosarcoma (misdiagnosed)*b (1), Retroperitoneal leiomyosarcoma*b (1), Primary malignant GCTB (misdiagnosed)* (1), Renal cancer (1), Circulatory collapse (1), Completed suicide (1) [*Malignant cases reviewed by an external expert panel.]


Denosumab was generally well tolerated with excellent long-term disease control in unresectable patients. A 27% recurrence rate following surgery was seen in this high-risk, resectable population (26% had recurrent GCTB at enrollment). Adverse events were consistent with the known profile for denosumab, with no unexpected long-term toxicities. Several cases of misdiagnosed as benign GCTB at enrollment were seen, reinforcing the need for careful expert pathologic evaluation of this rare disease at diagnosis. Denosumab has major, long-lasting antitumor activity in unresectable or metastatic GCTB.

Clinical trial identification


Legal entity responsible for the study

Amgen Inc.


Amgen Inc.


E. Palmerini: Amgen advisory board. J-Y. Blay: Research grants from Novartis, Roche, Pharmamar, Bayer, Ignyta, GSK, Lilly and Amgen, and has served as a consultant for Novartis, Roche, Pharmamar, Bayer, Ignyta, GSK, Lilly and Amgen A. Le Cesne: Consulting fees from Novartis, Pfizer, Lilly and Pharmamar. P. Reichardt: Advisory boards for Novartis, Pfizer, Bayer, PharmaMar, Ariad, Amgen, Inc., GlaxoSmithKline, AstraZeneca, Clinigen, and Lilly, and has received honoraria from Novartis, Pfizer, Bayer, PharmaMar, Amgen, Inc., GlaxoSmithKline, and Lilly. P. Rutkowski: Consultant for Amgen, MSD, BMS, Novartis and Roche and served on speaker’s bureaus for Novartis, Pfizer, BMS, MSD and Roche, and advisory board for Blueprint. H. Gelderblom: Institution has received grants and consultancy fees from Amgen. R.J. Grimer: Scientific advisory board for Amgen for this trial. A. Feng: Employee of Amgen during the time that this abstract was written. D. Jandial: Employee and Stockholder of Amgen. S. Chawla: Advisor and consultant for Amgen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.